Can, Turkey
Can, Turkey

Time filter

Source Type

News Article | November 16, 2016
Site: www.newsmaker.com.au

Cardiac Marker Analyzer, also known as Cardiac Reader Systems, provides high point-of-care testing solutions for the diagnosis of myocardial infarction and other cardiac-related diseases. It performs all cardiac monitoring tests, such as myoglobin and cardiac troponin tests, through immunochromatographic assays. A Cardiac Marker Analyzer increases its efficacy and accuracy with special features, such as software, which provides an internal standard to diagnostic procedures and built in LCD displays for the visualization of practices. Cardiac Marker Analyzers are important for the prevention of the misdiagnoses of cardiac conditions. . Some of the major Cardiac Marker Analyzers which are frequently used in diagnosis of cardiac conditions include QL Care Analyzer, Meritas POC Analyzer, PATHFAST Analyzer, Alere Meterpro Analyzer, RAMP Reader, RAMP 200, i–STAT System, Stratus CS Analyzer, Cobas H 232 POC System, Access 2 Immunoassay System, DXpress Reader Analyzer and ichroma DUO Analyzer. In terms of geographic, North America and Europe dominates the global Cardiac Marker Analyzer market. This is due to increasing prevalence of cardiac related diseases in these regions. The U.S. represents the largest market for Cardiac Marker Analyzer followed by Canada in North America. In Europe, France and Germany holds major share of Cardiac Marker Analyzer market. However, Asia is expected to show high growth rates in the next five years in the global Cardiac Marker Analyzer market due to increasing awareness among people about cardiovascular diseases. This increasing awareness increases the demand of Cardiac Marker Analyzer for diagnosis of heart diseases. In addition, less stringent regulatory environments attract manufacturing companies to construct their research facilities in the region which further support in the growth of Cardiac Marker Analyzer in the region. Japan, China and India are expected to be the fastest growing Cardiac Marker Analyzer markets in Asia. In recent time, increasing prevalence of cardiovascular diseases, such as angina pectoris and myocardial infarction, and technological advancement in marker technology are some of the major drivers for the global Cardiac Marker Analyzer market.  In addition, rising number of geriatric populations and technological advancement in cardiac assist devices are also supporting in the growth of global Cardiac Marker Analyzer market. Aged people are more susceptible towards cardiac diseases compared to youngster. Thus, geriatric people increase the demand of Cardiac Marker Analyzer for the management of their cardiac disorders. Moreover innovative applications of Cardiac Marker Analyzer, such as less time consuming practices and provides accurate diagnostic results, have also fueled the growth of the market. It takes less than 14 minutes to complete a diagnostic test. Increasing prevalence of diabetes and obese people develops opportunity for the global Cardiac Marker Analyzer market. However, stringent regulations and cost constrains are some of the major restraints of the global Cardiac Marker Analyzer market. In addition, presence of alternative technologies for the diagnosis of cardiac diseases also obstructs the growth of global Cardiac Marker Analyzer market. Increasing mergers and acquisitions between major players is key trend for the global Cardiac Marker Analyzer market. Some of the major companies operating in the global Cardiac Marker Analyzer market are Mitsubishi Chemical Medience Corporation, CardioGenics, Trinity Biotech, Lifesign, Abbott, Siemen Healthcare, Boditech and Beckman Coulter.


Adoue V.,French Institute of Health and Medical Research | Schiavi A.,McGill University | Light N.,McGill University | Almlof J.C.,Uppsala University | And 19 more authors.
Molecular Systems Biology | Year: 2014

Most complex disease-associated genetic variants are located in non-coding regions and are therefore thought to be regulatory in nature. Association mapping of differential allelic expression (AE) is a powerful method to identify SNPs with direct cis-regulatory impact (cis-rSNPs). We used AE mapping to identify cis-rSNPs regulating gene expression in 55 and 63 HapMap lymphoblastoid cell lines from a Caucasian and an African population, respectively, 70 fibroblast cell lines, and 188 purified monocyte samples and found 40-60% of these cis-rSNPs to be shared across cell types. We uncover a new class of cis-rSNPs, which disrupt footprint-derived de novo motifs that are predominantly bound by repressive factors and are implicated in disease susceptibility through overlaps with GWAS SNPs. Finally, we provide the proof-of-principle for a new approach for genome-wide functional validation of transcription factor-SNP interactions. By perturbing NFκB action in lymphoblasts, we identified 489 cis-regulated transcripts with altered AE after NFκB perturbation. Altogether, we perform a comprehensive analysis of cis-variation in four cell populations and provide new tools for the identification of functional variants associated to complex diseases. © 2014 The Authors.


PubMed | McGill University, Uppsala University, CardioGenics and French Institute of Health and Medical Research
Type: | Journal: Molecular systems biology | Year: 2014

Most complex disease-associated genetic variants are located in non-coding regions and are therefore thought to be regulatory in nature. Association mapping of differential allelic expression (AE) is a powerful method to identify SNPs with direct cis-regulatory impact (cis-rSNPs). We used AE mapping to identify cis-rSNPs regulating gene expression in 55 and 63 HapMap lymphoblastoid cell lines from a Caucasian and an African population, respectively, 70 fibroblast cell lines, and 188 purified monocyte samples and found 40-60% of these cis-rSNPs to be shared across cell types. We uncover a new class of cis-rSNPs, which disrupt footprint-derived de novo motifs that are predominantly bound by repressive factors and are implicated in disease susceptibility through overlaps with GWAS SNPs. Finally, we provide the proof-of-principle for a new approach for genome-wide functional validation of transcription factor-SNP interactions. By perturbing NFB action in lymphoblasts, we identified 489 cis-regulated transcripts with altered AE after NFB perturbation. Altogether, we perform a comprehensive analysis of cis-variation in four cell populations and provide new tools for the identification of functional variants associated to complex diseases.


Gawad Y.,CardioGenics
Medical Device and Diagnostic Industry | Year: 2010

Medical device products include disposable medical supplies, wound-management supplies, and diagnostic products. Immunoassays are chemical tests used to detect or quantify a specific substance, the analyte, in a blood or body fluid sample, using an immunological reaction. Proteins are released in blood when the heart is damaged. One vital application for cardiac markers is the point-of-care (POC) test market, encompassing those diagnostic tests that can be conducted at or near the site of patient care. A prime motivation for the development of new POC technology is the desire to reduce the time required to diagnose cardiac events such as heart attacks. When it comes to cardiac events and survival, the key factors for a successful recovery include the time required for diagnosis, the accuracy of that diagnosis, and appropriate clinical management.


CardioGenics | Entity website

Brief Company History CardioGenics was founded in Toronto, Ontario in 1997 as a biotechnology company dedicated to the development of products for the In-Vitro-Diagnostics market to meet unfulfilled needs. At the heart of CardioGenics Platform is a core technology for improving testing sensitivity to POC products ...


CardioGenics | Entity website

November 4, 2015 | Mississauga CardioGenics Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap MISSISSAUGA, Ontario - November 4, 2015 -CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it, and its newly created Canadian subsidiary, have entered into a definitive asset purchase agreement to acquire substantially all of the assets of Plasticap ...


CardioGenics | Entity website

Partners The Estapor Microspheres are manufactured in a state of the art facility which is located in Pithiviers about 40 miles south of Paris. Inaugurated in 2001, our new head office is located in Val de Fontenay, 5 miles east of Paris ...


CardioGenics | Entity website

GardioGenics Annual Meetings October, 2012 | Mississauga CardioGenics Annual Meeting 2012 Below are links to the Proxy Statement, Proxy Card and 10-K/A, which have been mailed to stockholders in connection with the Company's Annual Meeting to be held on October 17, 2012. Each document can be downloaded in PDF from their respective link ...


CardioGenics | Entity website

Pavel Zhelev Email : Tel: 905-673-8501 CardioGenics Inc. 6295 Northam Drive Unit 8, Mississauga, ON L4V 1W8

Loading CardioGenics collaborators
Loading CardioGenics collaborators